Breaking News

ArGEN-X, Shire Enter Long-term Strategic Pact

June 4, 2014

Shire invests $20.4 million in arGEN-X

ArGEN-X has entered into a long-term strategic alliance with Shire Pharmaceuticals that will employ its entire suite of human antibody discovery technologies to focus on multiple targets aligned with Shire's therapeutic candidates.
Shire will make a total upfront investment of $20.4 million in arGEN-X, and will fund the collaborative research programs at arGEN-X and pay fees, clinical, regulatory and sales milestones, as well as royalties on product sales. Shire will be responsible for clinical development and commercialization and arGEN-X has the right to license any programs not pursued by Shire.
"Our partnering philosophy at arGEN-X is to create alliances for the long term with select, top tier companies. We have certainly upheld this principle by repeatedly expanding our collaboration with Shire, with today's announcement marking our most ambitious and exciting venture with them to date," said Tim Van Hauwermeiren, chief executive officer of arGEN-X. "We have enjoyed consistent success in our collaboration, recognizing important synergies in combining our strengths and capabilities."
Dr. Philip J. Vickers, global head of R&D at Shire said, "Our arGEN-X collaboration has exceeded our expectations in delivering highly differentiated antibody programs within our therapeutic focus. The time is right to commit more significantly to the company through a longer term investment in its unique, world class technologies."

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent